Daniel Lynch is Director of SpringWorks Therapeutics, Inc.. Currently has a direct ownership of 305,944 shares of SWTX, which is worth approximately $12.7 Million. The most recent transaction as insider was on May 16, 2024, when has been sold 4,095 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 306K
0% 3M change
1.36% 12M change
Total Value Held $12.7 Million

DANIEL LYNCH Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 16 2024
BUY
Grant, award, or other acquisition
-
4,095 Added 1.32%
305,944 Common Stock
May 24 2023
BUY
Grant, award, or other acquisition
-
4,648 Added 1.52%
301,849 Common Stock
May 19 2022
BUY
Grant, award, or other acquisition
-
4,818 Added 1.6%
297,201 Common Stock
May 20 2021
BUY
Grant, award, or other acquisition
-
1,106 Added 0.38%
292,383 Common Stock

Also insider at

BLUE
bluebird bio, Inc. Healthcare
TSVT
2seventy bio, Inc. Healthcare
DL

Daniel Lynch

Director
Stamford,, CT

Track Institutional and Insider Activities on SWTX

Follow SpringWorks Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SWTX shares.

Notify only if

Insider Trading

Get notified when an Spring Works Therapeutics, Inc. insider buys or sells SWTX shares.

Notify only if

News

Receive news related to SpringWorks Therapeutics, Inc.

Track Activities on SWTX